Besides, Jacobson et al. showed that blockade of PD-L1 with the anti-PD-L1 antibody atezolizumab (atezo) significantly increased the efficacy and safety of ZUMA-6 in refractory DLBCL patients (190). The gene discussed is CD274; the disease is diffuse large B-cell lymphoma.